Yes, just one of many facts that bodes well for tiny BCLI. A VERY STRONG BUY IMO. Fact 1-Statically Significant Clinical Improvement in Patients with EARLY /LESS SEVERE who received NurOwn VS placebo as measured by THE Gold Standard ALSFRS-R physical function assessment. 2-Very Strong correlation between ALSFRS-R Stabilization or Improvement and BioMarker Data. This is fits perfectly with NurOwn’s theorized Mechanism of action AND the FDA has always show keen interest in the MOA of new treatments. 3-Approval of AMLX’s drug with less clinical data supporting clinical efficacy. 4-FDA’s Dr Dunn’s statement after AMLX approval: “This approval provides another important treatment option for ALS, a life-threatening disease that currently has no cure,” said Dr Billy Dunn, director of the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research, adding: “The FDA remains committed to facilitating the development of additional ALS treatments.” Hmmm ADDITIONAL ALS TREATMENTS..NurOwn?
5-VERY STRONG ADVOCACY